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Background Point of care tests (POCTs) for influenza potentially
offer earlier diagnosis, enabling specific treatment, infection
control measures and greater patient convenience and satisfaction.
Current POCTs have limited sensitivity, some cannot distinguish
influenza types, none differentiate subtypes and are relatively
expensive.
Aims To identify and characterise influenza POCTs expected to
be available for clinical use in the UK by mid-2013, highlighting
those with potential benefits over existing tests.
Methods Potential developers of influenza POCTs were
identified through known manufacturers’ websites, Medical
Technology trade associations, the EuroScan International
Network, an expert advisory group and by searching relevant
online sources. Identified companies were asked to provide
standard information on relevant technologies.
Results Fifty-six companies were identified, and 29 (52%)
responded, identifying 57 potentially relevant technologies. Of
these, 40 (70%) were already available or had undetermined status
and 5 (9%) were excluded as time to results took over
60 minutes. Of the remaining 12 emerging POCTs, 10 (83%)
reportedly enabled differentiation of influenza types and eight
differentiation of A subtypes. Nasopharyngeal swabs were the
most commonly acceptable sample type; the sample volume
ranging from 80 ll to 1Æ4 ml.
Discussion Most identified emerging influenza POCTs offered
differentiation of influenza type and subtype. Tests claiming this
capability include several incorporating reverse transcription
polymerase chain reaction assays; though, these also had the
longest time to result. However, whilst some identified POCTs
exhibit high sensitivity and specificity, most lack published clinical
data for assessment, and the overall costs of these technologies
remains largely unknown.
Keywords Diagnosis, emerging health technology, influenza,
innovation, point of care testing.
Please cite this paper as: Tayo A et al. (2012) Emerging point of care tests for influenza: innovation or status quo. Influenza and Other Respiratory Viruses
6(4), 291–298.
Background
In the United Kingdom, the majority of patients suffering
from influenza, who seek medical assistance, present in pri-
mary care.1 Diagnosis is routinely made on the basis of a
typical clinical syndrome (influenza like illness), which in
periods of high community influenza activity is considered
sufficiently reliable to guide the use of specific antiviral med-
ications; determine prognosis and the likelihood of serious
complications; and offer advice on infection control mea-
sures.2 At other times, and in cases where rapid action may
be necessary (e.g. to confirm an outbreak) or the presenta-
tion is atypical, diagnostic testing may be necessary. Current
practice requires that a suitable sample is transported in a
timely manner and an appropriate transport medium to a
laboratory for processing, testing and subsequent report-
ing.3,4 Depending on the setting, this may be logistically
difficult and introduces delays in clinical decision making.
Laboratory tests routinely employed for detection of influ-
enza viruses include virus culture, immunofluorescence (IF)
and reverse transcription polymerase chain reaction
(RT-PCR) assays.3,5 These have the capability to identify
and distinguish different influenza types and subtypes and
can be used with a wide range of acceptable specimen types.
Virus culture and RT-PCR assays are the gold standard for
influenza detection, demonstrating both sensitivity and
specificity. However, RT-PCR may take 4–6 hours to per-
form and virus culture may take up to 7 days for a result.
Diagnosis using IF can be achieved in 1–4 hours, but sensi-
tivity and specificity of detection by IF may be low.
In contrast, point of care tests (POCTs) allow both sam-
pling and analysis to take place in the same setting, and
the result is available without reference to a standard labo-
ratory.6,7 This encompasses tests requiring varying degrees
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of manual versus automated processing that can be cate-
gorised as non-instrumental disposable systems, single or
multireagent test strips, small hand-held analysers and lar-
ger desktop analysers for use in clinics.8 The World Health
Organisation (WHO) suggest an ideal POCT should be
affordable, sensitive, specific, rapid, robust, equipment-free
and delivered to those who need it.9 POCTs have the
potential to allow earlier diagnosis leading to earlier intro-
duction of specific treatment, establishment of effective
infection control measures and greater patient convenience,
involvement and satisfaction.10–12
In response to the perceived need for more rapid results
at the point of care to aid decision making, manufacturers
have marketed a number of POCTs for influenza viruses,
based on immunochromatographic assays, enzyme immu-
noassay or lateral flow assay to identify the influenza virus
antigen.13–15 However, laboratory confirmation of the
result is typically required. Current commercially available
tests, whilst showing specificity in the range 85–100%,
have been criticised for limited or variable sensitivity
(between 10% and 80% when compared to laboratory-per-
formed RT-PCR or viral culture for influenza),15–17 leading
to false-negative results, most notably when influenza
activity is high in the community. False-positive results
may also be obtained, particularly when the prevalence of
influenza in the community is low. Existing POCTs may
not distinguish between influenza types and do not differ-
entiate influenza subtypes,18 which could aid the manage-
ment of outbreaks, direct antiviral treatment (where
circulating subtypes have different antiviral susceptibilities),
allow identification of human infection with avian influ-
enza (in settings where this may be suspected) and provide
a useful surveillance tool. In addition, these tests may be
relatively expensive to perform per test and have a limited
shelf-life (1–2 years).19 There is therefore a need for a vali-
dated, sensitive and rapid POCT for influenza that also
has the capability to both reliably distinguish influenza A
and B, and influenza A subtypes. This need has been
recognised with the European Union (EU) Seventh Frame-
work Programme currently financing initiatives to develop
improved POCTs for influenza,20,21 and the development
of simple diagnostic tests is a research priority for the
WHO.22 We sought to identify and characterise emerging
POCTs for influenza that were expected to be available
and marketed for clinical use in the UK within the subse-
quent 3 years (by July 2013 at the latest) and to highlight
those with the potential to offer additional benefit over
currently available tests.
Methods
The review was carried out during May and June 2010.
Potential developers active in the field of point of care
testing for influenza were identified through interrogating
websites of known manufacturers of POCTs, through an
expert advisory group, through direct communications
with Medical Technology trade associations in the UK,
Europe and America and through members of the Euro-
Scan International network1 (Figure 1). In addition, a
search of online sources (see Box 1) was carried out using
pre-determined search terms.
Diagnostic tests for influenza were included if they were:
1. New or emerging, that is either CE marked ⁄FDA
approved or expected to be so within 2 years and ⁄or
for which marketing in the UK was planned to start
within 3 years.
2. They had a point of care application, that is were
being developed to be used in settings such as GP
surgeries, hospital wards, health units, pharmacies
and polyclinics.
3. And they had potential or claimed to add benefit
compared with existing technologies, for
example, improved accuracy, ability to identify
subtypes, rapid time to result and increased portability.
The main exclusion criterion was turnaround time to
results, with tests having turnaround times of more than
1 hour excluded.
Companies identified through the search that appeared
to have relevant products and ⁄or active development pipe-
Medical Technology
trade associations
Online searches
(Box 1)
EuroScan International
Network
Commercial
developers
Other sources, e.g.
CDC, Health Protection
Agency, and Health
Technology Assessment
agencies
Influenza tests
Review
criteria
Emerging point of care
tests
Excluded tests
MetNot met
Figure 1. Flowchart illustrating process of identifying point of care
tests for influenza currently in development and selecting those for
inclusion in the review.
1EuroScan is the international information network on new
and emerging health technologies (http://euroscan.org.uk).
It has 20 members who are situated in Europe, Scandina-
via, Israel, Australia and Canada.
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lines were contacted directly and asked to complete a pro
forma requesting information on relevant technologies such
as indication, intended place of use, size, sensitivity and
specificity. The review criteria were then applied to the tests
identified to develop a table of relevant tests. Advice from
an advisory group of experts was sought on clinical
relevance and ⁄or potential benefits.
Results
Fifty-six companies who were potentially developing point
of care diagnostic tests for influenza were initially identified
and contacted for further information. Twenty nine (52%)
of these companies responded, and from the information
provided, 57 technologies were identified as being poten-
tially relevant. Of these, 40 (70%) were either already avail-
able, newly launched (i.e. in the early stages of adoption) or
the status was undetermined. Five technologies (9%) took
over 60 minutes to produce a result, so were deemed not to
meet the review criteria. The remaining 12 (21%) were clas-
sified as emerging, that is had not yet been adopted by the
health system and appeared to meet the review criteria
(Table 1). Two of the tests came under the umbrella of the
research projects being financed by the EU Seventh Frame-
work to develop improved rapid POCTs for influenza.
Of the 12 tests that met the criteria, 10 (83%) were
reported to enable differentiation of influenza types A and
B, 8 (67%) were reported to enable differentiation of
selected influenza A subtypes [including H1N1(2009) in
seven cases and H3 in six cases], and one test was reportedly
specific for detection of human influenza A subtypes (with-
out differentiation) only. In addition, two tests also enabled
differentiation of H5 subtype viruses. Four tests were
reported to allow simultaneous running of more than one
sample at a time; nasopharyngeal swabs were the most com-
monly acceptable sample type, with 50% of the emerging
POCTs reporting use with this specimen type. Throat swabs,
nasal washes, aspirates and nasal swabs were also acceptable
for some POCTs. No information on acceptable sample type
was provided for three of the 12 emerging POCTs. The vol-
ume of clinical sample required for testing varied, ranging
from 80 ll to 1Æ4 ml where this information was provided.
Where time to result with the emerging POCTs was given,
the most rapid turnaround time for any of the POCTs was
within 15 minutes and ranged up to 1 hour.
Discussion
We identified 12 emerging POCTs for influenza; one (3M
Rapid Detection Flu test) has since been discontinued. Ele-
ven were reported to provide type and ⁄or subtype differen-
tiation, including identification of H1N1(2009) and H3 in
most cases. Tests claiming to offer this capability included
several which incorporate RT-PCR, in addition to those
which enhance currently available assays. Many of these
tests are also expected to be fully automated and in some
cases use closed systems (e.g. Liat influenza A ⁄ 2009 H1N1
assay and XPERT Flu A&B panel), which can reduce the
potential for human error and contamination, and those
using an RT-PCR methodology are reported to take from
45 minutes to 1 hour to produce a result. In a busy clinic,
this may itself represent a barrier to ‘point of care’ use,
requiring a patient to remain isolated in the clinic, whilst
results are awaited. In addition, whilst some of the identi-
fied emerging POCTs appear to have comparable sensitivity
and specificity for influenza with the ‘gold standard’
RT-PCR methodology,24,25 most currently lack published
clinical data on which to base an assessment. Improvement
in the negative predictive value and also the positive pre-
dictive value of emerging POCTs compared with currently
available POCTs is critical to their usefulness; though, it is
likely that laboratory confirmation will still be required at
times of low influenza activity (to reduce false-positive
results) and to confirm negative results. In addition, the
performance of individual tests and their effective use are
likely to depend on training and familiarity, use of suitable
sample type and appropriate quality assurance processes.26
The likely future cost of these tests once launched (includ-
ing the replacement costs and shelf-life of the consumable
components) is also unknown at present.
Box 1. Online sources searched to identify point of care tests for influenza currently in development
Diagnostic product listings (medical diagnostic websites)
Technology databases of horizon scanning and health technology assessment organisations.
Public Health Government Agencies: Health Protection Agency (HPA) and the Centers for Disease Control and Prevention (CDC).
Licensing organisations within and outside the European Union: list of products approved by the European Medicines Agency (EMA) and the
United States (US) Food and Drugs Administration (FDA).
Clinical trial databases of ongoing research of investigational products and technology transfer arms e.g. Medical Research Council (MRC)
Technology.
Bibliographic databases: Medline, Embase and the Cochrane library.
Internet search engine: Google.
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The methods used in this study rely on obtaining infor-
mation on technologies from developers.27 Good existing
relationships between the National Horizon Scanning Cen-
tre and the in vitro diagnostic industry, the comprehensive
search strategy and involvement of commercial trade asso-
ciations meant that we were able to produce a complete list
of likely large and medium sized commercial developers.
However, such developers may be unwilling or unable to
provide useful intelligence at an early stage of development
and may regard information as commercially confidential,
particularly on the performance of the test and marketing
plans. The majority of the tests identified were either being
developed by, or with the support of, a major in vitro diag-
nostic manufacturer. Tests may initially be developed by
individuals, academic institutions or small start-up compa-
nies, and those likely to be commercially successful are fre-
quently acquired by larger companies prior to market; as
such, it may be difficult to determine whether a company
or product development is still active, which may account
for the limited response to our information requests.
The adoption of POCTs for influenza into routine UK
clinical practice is currently limited by the poor perfor-
mance and high relative costs of currently available tests, as
well as the inability to distinguish influenza types and sub-
type; a truly innovative POCT would need to be rapid, able
to distinguish influenza A and B, differentiate key influenza
A subtypes and have a sensitivity equivalent to that of the
gold standard. We have identified a number of tests in a
late stage of development that have the potential to offer
benefits over the currently available options. In particular,
POCTs employing RT-PCR methodology may be available
and marketed over the next 1–2 years, and these have the
potential to overcome many of these barriers to more
widespread acceptance; though, their cost (as yet unknown)
and the time taken to produce a result may still limit their
diffusion into routine practice. The outcome of studies on
the clinical application and usefulness of these POCTs once
available will be of much interest.
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